Solid Tumor Testing Market Size To Reach Usd 12.1 Billion By 2031 | Key Trends & Forecasts

By Author: siddhesh
Total Articles: 242
Comment this article

Global solid tumor testing market is undergoing rapid transformation as oncology shifts decisively toward precision medicine and genomic-guided therapies. Valued at USD 6.8 billion in 2024, the market is projected to reach USD 12.1 billion by 2031, expanding at a strong CAGR of 8.5%, driven by rising cancer incidence, personalized treatment pathways, and technological advancements in molecular testing.
Read more on https://www.24lifesciences.com/solid-tumor-testing-market-9012
Emerging Healthcare Trends Reshaping Solid Tumor Diagnostics
The solid tumor testing market is benefiting from a new wave of healthcare innovation in 2025. Growing adoption of next-generation sequencing (NGS), expansion of AI-supported clinical diagnostics, and deeper integration of molecular profiling in oncology workflows are creating a more efficient and data-driven cancer care ecosystem.
AI-assisted pathology systems and predictive diagnostic algorithms are improving early detection accuracy, while tele-oncology platforms are enabling wider access to molecular testing in remote and underserved regions. Global momentum toward ...
... personalized care, coupled with strong advancements in tumor biomarker discovery, is accelerating the shift toward tailored therapeutic decisions.

Key Market Drivers Supporting Global Growth
Several powerful forces are shaping the market trajectory:
• Technological Advancements: NGS, PCR, and immunohistochemistry are enabling broader and more detailed tumor profiling with faster turnaround times.
• Rising Global Cancer Burden: Increasing incidence across lung, breast, colorectal, and prostate cancers is fueling diagnostic demand.
• Expanding Precision Oncology Ecosystem: Targeted therapies and immunotherapies rely on accurate biomarker identification, making molecular testing indispensable.
• Government & Institutional Initiatives: National cancer programs and public-private partnerships are strengthening genomic infrastructure.
• Shift Toward Value-Based Care: Hospitals and oncology networks are prioritizing accurate diagnostics to support cost-effective and personalized treatment plans.
Together, these factors reinforce solid tumor testing as a foundational pillar of modern oncology.
Download the full dataset https://www.24lifesciences.com/download-sample/9012/solid-tumor-testing-market
Competitive Landscape: Leading Companies Driving Innovation
Key companies shaping global industry dynamics include:
• F. Hoffmann-La Roche Ltd.
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• Danaher Corporation (Beckman Coulter)
These industry leaders continue to invest heavily in genomic technologies, liquid biopsy development, companion diagnostics, and integrated oncology platforms. Strategic collaborations, R&D expansion, and clinical workflow automation remain central to their long-term growth priorities.

Segment Insights & Regional Market Overview
By Type
Non-Conventional Testing dominates the market, fueled by widespread adoption of advanced molecular diagnostics, sequencing-based platforms, and biomarker-driven testing models. These technologies outperform traditional histopathology by offering deeper insights into tumor genetics and actionable mutations.
By Application
Hospitals remain the leading application segment due to their role as primary cancer care hubs. High patient volumes, comprehensive oncology centers, and access to multidisciplinary teams underpin this dominance.
By End User
Oncologists constitute the largest end-user group, relying on detailed tumor profiling to guide treatment planning, therapy selection, and disease monitoring.
By Technology Platform
Next-Generation Sequencing (NGS) stands as the most influential platform, enabling multi-gene panel testing, whole-exome and whole-genome sequencing, and high-throughput biomarker analysis.
By Tumor Profiling Purpose
Therapeutic Selection leads due to the rising global use of targeted therapies and immunotherapies that require precise biomarker validation before initiation.
Explore analytics https://www.24lifesciences.com/solid-tumor-testing-market-9012
Regional Overview
• North America remains the global leader, driven by advanced precision medicine programs, high healthcare spending, and rapid adoption of NGS and companion diagnostics.
• Europe follows with strong institutional support, well-established cancer care frameworks, and increasing standardization under evolving IVDR guidelines.
• Asia-Pacific is the fastest-growing region, powered by rising cancer incidence, expanding genomic infrastructure, and government-led innovation in China and Japan.
• South America shows steady growth, led by Brazil, as oncology centers modernize diagnostic capabilities.
• Middle East & Africa presents a mixed landscape — with high-end adoption in GCC nations and early-stage development across parts of Africa.

Can AI-Driven Care Models Reshape the Future of Solid Tumor Testing?
AI-enabled clinical decision systems, digital pathology, and real-time biomarker analytics are expected to redefine how clinicians diagnose, treat, and monitor solid tumors in the coming decade. Predictive modeling, automated image interpretation, and cloud-based genomic platforms will enhance the precision, accessibility, and speed of cancer diagnostics globally.

Key Benefits of the Full Report
• Extensive segmentation and competitive analysis
• Accurate CAGR-based market forecasts through 2031
• Insight into technology adoption across global markets
• Emerging opportunities in precision oncology and genomic testing
• Strategic guidance for investors and healthcare organizations
View market insight https://www.24lifesciences.com/solid-tumor-testing-market-9012
Future Perspective
As healthcare systems worldwide accelerate their transition toward personalized cancer care, the solid tumor testing market is positioned for significant expansion. Advancements in sequencing technologies, ongoing biomarker discoveries, and robust oncology investments will continue to unlock new growth avenues for stakeholders across diagnostics, biopharma, and clinical care ecosystems.
Explore Life sciences Related Ongoing Coverage in Healthcare Domain:

1.5T Helium-Free MRI System Market
Prostaglandin endoperoxide Synthase 2 (COX-2) ELISA Kit Market
Ribbon Retractor Market
Long Term Care Provider Market
PSA Test Market
Cervical Dilator Market
Varicella Vaccine Market
Urine Analyzer Market
Bladder Scanners Market
Cardiac Monitoring & Cardiac Rhythm Management Market

About 24lifesciences
Founded in 2017, 24LifeScience has emerged as a trusted research and analytics partner for organizations operating within the global life sciences and chemical industries. Our core mission is to provide intelligent, future-ready insights that help clients stay ahead in an increasingly complex and innovation-driven market
International: +1(332) 2424 294 | Asia: +91 9425150513 (Asia)
Website: http://www.24lifesciences.com
Follow us on LinkedIn: http://www.linkedin.com/company/lifesciences24